Quick Facts: Uses of Lacrimal Devices

• Support for Tear Drainage: Used to help re-establish and maintain the pathway for tear fluid drainage.
• Managing Obstruction: Applied in the management of specific obstructions within the nasolacrimal duct system.
• Post-Surgical Healing: Used following certain procedures, such as dacryocystorhinostomy (DCR), to assist in the healing process.

---

Lacrimal devices, which may include stents, intubation sets, or balloon catheters, are specialized products utilized within the ophthalmic field. These tools serve the therapeutic purpose of managing conditions affecting the tear drainage system. Specifically, they are indicated for the management of acquired obstruction in the lacrimal sac and duct, which can lead to excessive tearing, known as epiphora.

Lacrimal devices are applied in procedures intended to open or bypass blockages in the tear drainage pathway, including those resulting from canalicular pathologies like stenosis (narrowing), obstruction, or laceration. They may also be used in cases of congenital nasolacrimal duct obstruction in infants when initial non-surgical approaches do not yield improvement. The function of these devices is to maintain patency during the healing phase of the lacrimal system.

The official eligibility profile for Lacrimal (Ophthalmic Lubricants) is primarily defined by the medicine's topical, non-systemic action, which results in negligible systemic absorption. This is reflected in regulatory documentation, which places limited restrictions on its use.

Eligibility Classification	Status	Rationale per Regulatory Documents
Absolute Contraindication	Not Permitted	Use is absolutely contraindicated in patients with known hypersensitivity or allergy to the active substance (e.g., sodium hyaluronate, cellulose ethers) or to any excipients in the formulation.
Age-Group Eligibility	Established/Not Recommended	Use is established for adults and older adults. However, use in the pediatric population (e.g., under 18 years) is often not recommended by regulatory bodies due to a documented lack of specific clinical experience.
Organ Impairment	No Restriction	No specific restrictions are documented for patients with hepatic (liver) or renal (kidney) impairment, as the medicine is not systemically absorbed.
Pregnancy/Lactation	Permitted	No adverse effects are anticipated during pregnancy or breastfeeding, as the negligible systemic exposure is not expected to affect the foetus or infant.

Official labeling also notes that specific formulations containing certain preservatives require that soft contact lenses be removed prior to instillation; this is a conditional restriction on use.

Interactions with other medicines and products

This section outlines documented interactions for Lacrimal (a radiotracer) based strictly on official governmental regulatory documents, focusing on how concomitant medicinal products may affect the product’s use in diagnostic procedures.

---

Documented Interaction Categories and Implications

Interacting Product Category	Regulatory Statement and Implication
Diuretics	Administration of a diuretic expected to act within the radiotracer uptake period may be considered at the time of injection. The intent is a procedural modification to potentially decrease artifact from radiotracer accumulation within the urinary bladder and ureters for improved image quality.
Androgen Deprivation Therapy and Other Androgen Pathway Therapies	These therapies can result in changes in uptake of the radiotracer. This information is a critical consideration for the correct interpretation of the diagnostic imaging results.

---

Official Interaction Structure

The regulatory information structures the interaction profile around requirements essential for the diagnostic procedure. For Diuretics, the interaction is framed as an optional, procedure-related action to optimize imaging conditions by managing the physical distribution of the radiotracer. In the case of Androgen Deprivation Therapy, the documented interaction is a substantive observation that mandates factoring in altered radiotracer uptake during the interpretation phase. This profile does not detail pharmacokinetic drug-drug interactions, but instead defines constraints for maximizing the accuracy of the imaging test.

Lacrimal functions as a calcineurin inhibitor, primarily targeting the T-cell activation pathway. Following ocular administration and penetration into the lacrimal gland and conjunctiva, the active compound binds to the intracellular protein cyclophilin. This formed complex then binds to and inhibits calcineurin, a calcium-dependent phosphatase.

Inhibition of calcineurin prevents its dephosphorylation of the nuclear factor of activated T-cells (NFAT). Because NFAT remains phosphorylated, its nuclear translocation is blocked, and it is unable to bind to the promoter regions of various cytokine genes. This mechanical block restricts the transcription and subsequent expression of pro-inflammatory cytokines, including Interleukin-2 (IL-2). The resultant intracellular cascade reduces the recruitment and activation of T-cells and other inflammatory cell types within the ocular surface and associated glandular tissues. This localized immunomodulation affects cellular processes that govern basal tear fluid and protein secretion, leading to an alteration in glandular secretory function.

How to Properly Apply Lacrimal (Ophthalmic Solution)

Lacrimal, an ophthalmic solution containing a lubricating agent like hydroxypropyl methylcellulose, is used to temporarily relieve dryness and irritation of the eye. Proper application technique is crucial to ensure efficacy and maintain the sterility of the product.

---

Application Procedure

Follow these steps for the correct instillation of the eye drops:

1. Hand Hygiene: Thoroughly wash your hands with soap and water before handling the medication to prevent contamination of the bottle or solution.
2. Positioning: Tilt your head back, look upward, and gently pull down the lower eyelid to create a small pouch.
3. Instillation: Hold the dropper tip directly over the eye. Squeeze or press the container gently to dispense one or two drops into the lower eyelid pouch, as directed by a healthcare professional or the product label. Avoid allowing the dropper tip to touch the eye, eyelid, or any other surface.
4. Absorption: Gently close your eye for one to two minutes after instillation. Applying gentle pressure with a finger to the corner of the eye near the nose may help prevent the medication from draining away.
5. Storage: Tightly replace the cap immediately after use. Store the container at room temperature, away from excessive heat and moisture.

---

Important Safety Considerations

• Dosage: The typical recommended frequency for ophthalmic solutions is one or two drops as needed, or up to four times a day, though this may vary. Always follow your prescribed dosing schedule.
• Contact Lenses: If you wear soft contact lenses, you must remove them before applying the drops unless specifically advised otherwise by your eye care professional. Wait at least 15 minutes before reinserting them.
• Discontinue Use: Stop using the product and consult a healthcare professional if you experience eye pain, vision changes, continued redness, irritation, or if the condition worsens or persists beyond 72 hours.
• Contamination: Do not use the solution if it changes color or becomes cloudy. Single-use containers should be discarded immediately after use and never reused.

Lacrimal: Recent Clinical Evidence

The field of lacrimal (tear film) treatments has seen recent developments focused on both stimulating natural tear production and stabilizing the tear film to reduce evaporation.

Tear Neurostimulation and Production

Recent clinical trials have investigated novel approaches to increase tear production. One approach involves using a nasal spray formulation to activate the trigeminal parasympathetic pathway, which is understood to stimulate the lacrimal functional unit. Integrated analysis of two pivotal randomized clinical trials, known as ONSET-1 and ONSET-2, evaluated this method in patients with varying severities of Dry Eye Disease (DED). The analysis noted that, compared with vehicle control, this method was associated with improvements in both tear production (measured by Schirmer testing) and patient-reported symptoms.

Tear Film Stability

Another focus is on therapies designed to treat DED associated with Meibomian Gland Dysfunction (MGD), which often leads to rapid tear evaporation. A first-in-class ophthalmic solution, comprised of 100% perfluorohexyloctane, was studied to specifically target and stabilize the tear film's lipid layer. This water-free and preservative-free therapy aims to prevent excessive tear evaporation and restore tear film balance. Clinical data documented a rapid reported decrease in dryness symptoms after the administration of these drops.

Anti-inflammatory and Regenerative Studies

Studies continue to explore anti-inflammatory strategies and regenerative techniques for severe DED. For instance, Platelet-Rich Plasma (PRP) injection into the lacrimal gland was evaluated in a comparative clinical study for severe DED, particularly in cases linked to Sjögren’s syndrome. Objective assessments, including non-invasive tear break-up time (NITBUT) and Tear Meniscus Height (TMH), showed statistically significant differences in favor of the PRP group after one and three months compared to the control group, suggesting that further research may be warranted in this area.

Common questions about Lacrimal (FAQ)

Q: What is Lacrimal, and what is it used for?

A: Lacrimal is a prescription medication often used in the management of certain eye conditions, particularly those involving dry eyes or issues with tear production and stability. Its primary function is to help lubricate the surface of the eye, providing relief from dryness, irritation, and discomfort associated with conditions like keratoconjunctivitis sicca (chronic dry eye syndrome).

It works to replace or supplement the natural tear film, protecting the cornea and conjunctiva, and may also be used to facilitate healing after certain eye procedures or injuries.

---

Q: How do I properly apply Lacrimal eye drops or ointment?

A: For eye drops:

1. Wash your hands thoroughly before use.
2. Tilt your head back or lie down and look up.
3. Pull down your lower eyelid gently to form a small pocket.
4. Hold the dropper bottle above the eye and squeeze out one drop into the pocket.
5. Close your eye gently and press a finger to the inner corner of your eye near the nose for one or two minutes. This helps keep the medication in the eye.

For eye ointment:

1. Wash your hands thoroughly.
2. Tilt your head back and look up.
3. Pull down your lower eyelid to create a small pocket.
4. Squeeze a small strip (about a quarter to a half inch) of ointment into the pocket.
5. Close your eye for one to two minutes.

Important: Do not touch the tip of the container to your eye, fingers, or any other surface to avoid contamination.

---

Q: Can Lacrimal interact with other eye medications?

A: Yes, Lacrimal may interact with other eye medications. If you are using more than one type of eye medication (such as other drops or ointments), it is generally recommended to space out the applications by at least five to ten minutes.

• Eye drops should typically be applied before eye ointments.
• Applying other medications too closely together may wash out the Lacrimal or prevent proper absorption.

Always inform your healthcare provider about all medications, including over-the-counter and herbal products, that you are using.

---

Q: What are the common side effects of Lacrimal?

A: Most people use Lacrimal without experiencing serious side effects. The most common side effects are usually mild and temporary and often relate to the eye itself.

Commonly reported side effects include:

• Temporary blurred vision immediately after application.
• Mild stinging, burning, or irritation of the eye.
• Feeling like something is in the eye (foreign body sensation).
• Increased tearing (watery eyes).

If these effects persist or worsen, you should consult with a healthcare professional. Less common, but more serious, reactions should be reported immediately.

The storage and disposal of Lacrimal (Ophthalmic Lubricants) must strictly follow official regulatory guidelines to maintain product integrity and safety.

Storage Requirements

• Temperature: Store the product at controlled room temperature, typically 20 to 25 C. The solution must not be frozen.
• Protection: Keep the bottle tightly closed in the original container and protect from light.
• Child Safety: Always store the medicine safely out of the sight and reach of children.

Stability and Disposal

Once opened, the solution must be discarded after one month to reduce the risk of contamination. Unused or expired eye drops must not be thrown away in household waste or wastewater. Instead, dispose of the product according to local pharmaceutical waste collection programs.